Adrenocortical Carcinoma with Hypercortisolism

Endocrinol Metab Clin North Am. 2018 Jun;47(2):395-407. doi: 10.1016/j.ecl.2018.02.003. Epub 2018 Apr 9.

Abstract

Adrenocortical carcinoma (ACC) is a rare and aggressive tumor. ACC may be associated with different syndromes of hormone excess, most frequently Cushing's syndrome with or without hypersecretion of androgens. Recent data suggest that cortisol excess is a negative prognostic factor in advanced and localized ACC. Surgery with radical intent, when feasible, is the most effective treatment for ACC with hypercortisolism. Mitotane is the medical treatment of choice, both postoperatively and in inoperable or metastatic cases. Because of its slow onset of action, combination with other antisecretory agents (ie, metyrapone) is helpful to achieve more rapid and effective control of hypercortisolism.

Keywords: Adrenocortical carcinoma; Cortisol; Cushing’s syndrome; Mitotane.

Publication types

  • Review

MeSH terms

  • Adrenocortical Carcinoma* / complications
  • Adrenocortical Carcinoma* / diagnosis
  • Adrenocortical Carcinoma* / drug therapy
  • Adrenocortical Carcinoma* / surgery
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Cushing Syndrome* / diagnosis
  • Cushing Syndrome* / drug therapy
  • Cushing Syndrome* / etiology
  • Cushing Syndrome* / surgery
  • Humans

Substances

  • Antineoplastic Agents, Hormonal